0001193125-23-079964.txt : 20230327 0001193125-23-079964.hdr.sgml : 20230327 20230327095955 ACCESSION NUMBER: 0001193125-23-079964 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230323 ITEM INFORMATION: Bankruptcy or Receivership ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230327 DATE AS OF CHANGE: 20230327 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Codiak BioSciences, Inc. CENTRAL INDEX KEY: 0001659352 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39615 FILM NUMBER: 23761751 BUSINESS ADDRESS: STREET 1: 35 CAMBRIDGEPARK DRIVE STREET 2: SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: 617-949-4100 MAIL ADDRESS: STREET 1: 35 CAMBRIDGEPARK DRIVE STREET 2: SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02140 FORMER COMPANY: FORMER CONFORMED NAME: Codiak Biosciences, Inc. DATE OF NAME CHANGE: 20151125 8-K 1 d467120d8k.htm 8-K 8-K
false 0001659352 0001659352 2023-03-23 2023-03-23

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported):

March 23, 2023

 

 

Codiak BioSciences, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39615   47-4926530

(State or other jurisdiction of

incorporation or organization)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification Number)

35 CambridgePark Drive, Suite 500

Cambridge, MA 02140

(Address of principal executive offices and zip code)

(617) 949-4100

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share   CDAK   Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 1.03.

Bankruptcy or Receivership.

On March 27, 2023, Codiak BioSciences, Inc. (the “Company”) filed a voluntary petition (the “Bankruptcy Petition”) for relief under Chapter 11 of Title 11 (“Chapter 11”) of the United States Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), thereby commencing a Chapter 11 case for the Company (Case No. 23-10350). The Company continues to operate its business as a “debtor-in-possession” under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Bankruptcy Court. The Company is seeking approval of a variety of “first day” motions containing customary relief intended to enable the Company to continue its ordinary course operations. The Company intends to sell substantially all of its assets during the bankruptcy case.

 

Item 2.05.

Costs Associated with Exit or Disposal Activities.

On March 23, 2023, the board of directors (the “Board”) of Codiak BioSciences, Inc. approved a restructuring of operations and corresponding reduction in workforce, designed to reduce costs and reallocate resources while maintaining the personnel needed to support the Company’s key programs and refocused pipeline, including the wind down of the Company’s clinical trial for exoASO™-STAT6, while the Company explores strategic alternatives (the “Restructuring”). The Restructuring reduced the Company’s workforce by thirty-four (34) employees, or 69%, with the reductions in personnel expected to be completed by April 7, 2023. The Company expects to provide severance payments to the affected employees. The Company also plans to enter into retention arrangements with certain employees who are expected to remain with the Company to assist with its exploration of strategic alternatives. The Company estimates that it will incur approximately $1,120,000 of costs in connection with the reduction in workforce related to severance pay and other related termination benefits. The costs related to the Restructuring are subject to a number of assumptions, and actual results may differ materially. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the Restructuring.

 

Item 5.02.

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

In connection with the Restructuring discussed in Item 2.05 above, the following members of the Company’s executive team will be leaving the Company to pursue new opportunities: (i) Douglas E. Williams, Ph.D., President and Chief Executive Officer, (ii) Linda C. Bain, Chief Financial Officer and Treasurer, (iii) David Mauro, M.D., Ph.D., Chief Medical Officer, (iv) Sriram Sathyanarayanan, Ph.D., Chief Scientific Officer, (v) Yalonda Howze, Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary, and (iv) Nicole Barna, Senior Vice President, Human Resources. Ms. Howze notified the Company of her resignation from her position, to be effective as of April 4, 2023, on March 24, 2023. The departures of Dr. Williams, Ms. Bain, Dr. Mauro, Dr. Sathyanarayanan and Ms. Barna will be effective as of April 7, 2023. The Company plans to enter into consulting agreements with each of Dr. Williams, Ms. Bain, Dr. Mauro, Dr. Sathyanarayanan, Ms. Howze and Ms. Barna.

Dr. Williams will continue to serve as a director of the Company.

The Company would like to thank Dr. Williams, Ms. Bain, Dr. Mauro, Dr. Sathyanarayanan, Ms. Barna and Ms. Howze for their commitment and guidance to the Company.

In connection with their departures, the executives will be entitled to certain severance payments. Ms. Bain will be entitled to a severance payment of $74,254, Dr. Mauro will be entitled to a severance payment of $55,200, Dr. Sathyanarayanan will be entitled to a severance payment of $68,169, and Ms. Barna will be entitled to a severance payment of $59,119.

 

Item 8.01.

Other Events.

On March 27, 2023, the Company issued a press release announcing its Bankruptcy Petition and related matters. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

Cautionary Note Regarding Forward-Looking Statements

This report, including the exhibits hereto, contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, among other things, statements regarding the expected cost-savings from the Restructuring and the expecting timing for incurring costs associated with the Restructuring, the expected timing of implementing and completing the Restructuring and the Bankruptcy Petition, the Company’s plans to retain certain individuals as employees or consultants to assist in this process, and the potential for and timing of the consummation of sales of the Company’s assets or other strategic alternatives. Any forward-looking statements in this report, including the exhibits hereto, are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including, but not limited to, the risk that the Company may not be able to implement the Restructuring or the exploration of strategic alternatives under the Bankruptcy Petition as currently anticipated or within the timing currently anticipated, the impact of the workforce reduction on the Company’s business, the risk that the Company’s cost saving initiatives may not be successful, unanticipated difficulties with preserving capital, unanticipated difficulties in terminating certain contracts and arrangements, unanticipated charges not currently contemplated that may occur as a result of the Restructuring, and the risk that the Company may not be successful in identifying one or more strategic alternatives or ultimately pursuing a strategic alternative that delivers the anticipated benefits. For a discussion of these risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and in subsequent filings with the Securities and Exchange Commission (“SEC”), as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the SEC. All information in this report, including the exhibits hereto, is current as of the date of this report, and the Company undertakes no duty to update this information unless required by law.

 

Item 9.01.

Financial Statements and Exhibits.

(d)    Exhibits

 

Exhibit

Number

    Description
99.1    Press release, dated March 27, 2023, issued by Codiak BioSciences, Inc.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 27, 2023     Codiak BioSciences, Inc.
    By:  

/s/ Douglas E. Williams

    Name:   Douglas E. Williams, Ph.D.
    Title:   Chief Executive Officer and President
 EX-99.1 2 d467120dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO  

Codiak BioSciences to Pursue Asset Sale through Voluntary Chapter 11 Process

CAMBRIDGE, Mass., March 27, 2023 — Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that the Company has voluntarily filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware and will seek to pursue a sale process for its assets which is intended to maximize the value of the Company.

The Company began a marketing process ahead of the Chapter 11 filing to determine the level of market interest and is in ongoing discussions with several parties. The Company expects to consummate a sale of the entire business or its core assets as soon as reasonably practicable.

“The Board and management team have thoroughly assessed all of our strategic options and believe that this structured process represents the best possible solution for Codiak, taking into account our financial needs and the stage of our clinical and research programs,” said Douglas E. Williams, Ph.D., President and Chief Executive Officer of Codiak.

In connection with the filing, Codiak has appointed Paul Huygens, Principal at Province, LLC, as Chief Restructuring Officer. Mr. Huygens will oversee the business and its restructuring process, working to execute the Company’s business strategy and conduct a value-maximizing sale process. Mr. Huygens brings deep experience in managing complex financial and operational restructurings, including providing interim management services to preserve and maximize value.

The Company’s executive management team, including Dr. Williams, Linda C. Bain (Chief Financial Officer and Treasurer), David Mauro, M.D., Ph.D. (Chief Medical Officer), Sriram Sathyanarayanan, Ph.D. (Chief Scientific Officer), and Nicole Barna (Senior Vice President, Human Resources), will be departing the Company effective April 7; Dr. Williams will remain on the Board. Yalonda Howze (Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary) will be departing the Company on April 4. Konstantin Konstantinov, Ph.D. (Chief Technology Officer) will remain with the Company.

The Company will be filing various “First-Day” motions with the Bankruptcy Court requesting customary relief that will enable the Company to transition into Chapter 11 without disruption to its ordinary course operations. Codiak expects these motions to be approved within the first few days of the case.

Codiak is represented in this matter by Young Conaway Stargatt & Taylor, LLP as legal advisors, and Province, LLC as financial advisor and provider of interim management services.

About Codiak BioSciences

Codiak is a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx® Platform to expand upon the innate properties of

exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx® Platform to generate a pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, infectious disease and rare disease.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, among other things, statements concerning the Company’s ability to consummate a sale of the entire business or its core assets. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion of these risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Codiak’s Annual Report on Form 10-K for the year ended December 31, 2021, as well as discussions of potential risks, uncertainties and other important factors in Codiak’s subsequent filings with the Securities and Exchange Commission (SEC). All information in this press release is current as of the date of this report, and Codiak undertakes no duty to update this information unless required by law.

Contact:

Christopher Taylor

Codiak BioSciences

E: investor@codiakbio.com

#    #    #

EX-101.SCH 3 cdak-20230323.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 cdak-20230323_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 cdak-20230323_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g467120g0327065712313.jpg GRAPHIC begin 644 g467120g0327065712313.jpg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htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
Mar. 23, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001659352
Document Type 8-K
Document Period End Date Mar. 23, 2023
Entity Registrant Name Codiak BioSciences, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39615
Entity Tax Identification Number 47-4926530
Entity Address, Address Line One 35 CambridgePark Drive
Entity Address, Address Line Two Suite 500
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02140
City Area Code (617)
Local Phone Number 949-4100
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol CDAK
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 8 d467120d8k_htm.xml IDEA: XBRL DOCUMENT 0001659352 2023-03-23 2023-03-23 false 0001659352 8-K 2023-03-23 Codiak BioSciences, Inc. DE 001-39615 47-4926530 35 CambridgePark Drive Suite 500 Cambridge MA 02140 (617) 949-4100 false false false false Common Stock, par value $0.0001 per share CDAK NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.codiakbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d467120d8k.htm cdak-20230323.xsd cdak-20230323_lab.xml cdak-20230323_pre.xml d467120dex991.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d467120d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "d467120d8k.htm" ] }, "labelLink": { "local": [ "cdak-20230323_lab.xml" ] }, "presentationLink": { "local": [ "cdak-20230323_pre.xml" ] }, "schema": { "local": [ "cdak-20230323.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cdak", "nsuri": "http://www.codiakbio.com/20230323", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d467120d8k.htm", "contextRef": "duration_2023-03-23_to_2023-03-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.codiakbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d467120d8k.htm", "contextRef": "duration_2023-03-23_to_2023-03-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.codiakbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.codiakbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.codiakbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.codiakbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.codiakbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.codiakbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.codiakbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.codiakbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.codiakbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.codiakbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.codiakbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.codiakbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.codiakbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.codiakbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.codiakbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.codiakbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.codiakbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.codiakbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.codiakbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.codiakbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.codiakbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.codiakbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.codiakbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.codiakbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001193125-23-079964-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-079964-xbrl.zip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end